The total return over the past 12 months is -49.59% vs. +16.94% for the S&P 500. So far it's up -24.63% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (49.59%) | (34.77%) | N/A | N/A | N/A | N/A |
| Total Return CAGR | (49.59%) | (34.77%) | N/A | N/A | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
CytoMed Therapeutics Limited (GDTC)
| Year | Start price | End price | GDTC Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $1.34 | $1.01 | (24.63%) | +14.51% | (39.14%) |
| 2025 | $3.40 | $1.34 | (60.59%) | +17.72% | (78.31%) |
| 2024 | $4.90 | $3.40 | (30.61%) | +24.89% | (55.50%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
